Biologic Agents for the Treatment of Chronic Rhinosinusitis With Nasal Polyps.
Am J Rhinol Allergy
; 33(2): 203-211, 2019 Mar.
Article
em En
| MEDLINE
| ID: mdl-30587005
ABSTRACT
BACKGROUND:
Chronic rhinosinusitis with nasal polyposis is a complex inflammatory disorder, which is often recalcitrant to medical and surgical management. Recently, biologic agents have been studied as an adjunct treatment for this patient population.OBJECTIVE:
The purpose of this study is to examine the role of biologic agents for chronic rhinosinusitis patients by reviewing literature and clinical trials.METHODS:
A comprehensive review of literature and clinical trials-both recently completed and ongoing-was undertaken to examine up-to-date evidence of current biologic therapy and its role in chronic rhinosinusitis patients-including anti-IgE, anti-IL-4, anti-IL-5, anti-IL-13, and GATA-3 DNAzyme.RESULTS:
Specific biologic agents discussed include omalizumab, reslizumab, mepolizumab, benralizumab, dupilumab, and Hgd40/SB010. Risks, side effects, and administration information are also reviewed. An algorithm for the use of biologics in patients with chronic rhinosinusitis with nasal polyposis is proposed.CONCLUSION:
These treatments have promising results and may prove to be an important adjunct for patients with recalcitrant sinus disease.Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Sinusite
/
Terapia Biológica
/
Rinite
/
Pólipos Nasais
/
DNA Catalítico
/
Anticorpos Monoclonais
Idioma:
En
Ano de publicação:
2019
Tipo de documento:
Article